Results 31 to 40 of about 382,649 (338)

Case Report: Clinical and Hematological Characteristics of εγδβ Thalassemia in an Italian Patient

Frontiers in Pediatrics, 2022
Introductionεγδβ thalassemia is a rare form of β-thalassemia mostly described in children originating from Northern Europe. Only anecdotic cases from the Mediterranean area are reported. The diagnosis is challenging, considering the rarity of the disease
Ilaria Fotzi, Francesco Pegoraro, Francesco Pegoraro, Elena Chiocca, Tommaso Casini, Massimo Mogni, Marinella Veltroni, Claudio Favre   +7 more
doaj   +1 more source

An injectable bone marrow–like scaffold enhances T cell immunity after hematopoietic stem cell transplantation

Nature Biotechnology, 2019
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for multiple disorders, but deficiency and dysregulation of T cells limit its utility.
Nisarg J. Shah, Angelo S. Mao, Ting-Yu Shih, Matthew D. Kerr, A. Sharda, Theresa M. Raimondo, J. Weaver, V. Vrbanac, M. Deruaz, A. Tager, D. Mooney, D. Scadden   +11 more
semanticscholar   +1 more source

Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.

Blood, 2017
An international expert panel, active within the European Society for Blood and Marrow Transplantation, European LeukemiaNet, Blood and Marrow Transplant Clinical Trial Group, and the International Myelodysplastic Syndromes Foundation developed ...
T. D. Witte, D. Bowen, M. Robin, L. Malcovati, D. Niederwieser, I. Yakoub-Agha, G. Mufti, P. Fenaux, G. Sanz, R. Martino, E. Alessandrino, F. Onida, A. Symeonidis, J. Passweg, G. Kobbe, A. Ganser, U. Platzbecker, J. Finke, M. Gelder, A. A. Loosdrecht, P. Ljungman, R. Stauder, L. Volin, H. Deeg, C. Cutler, W. Saber, R. Champlin, S. Giralt, C. Anasetti, N. Kröger   +29 more
semanticscholar   +1 more source

Busulfan in Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation, 2009
The development of intravenous busulfan (Bu) and its incorporation in the preparative regimens for allogeneic stem cell transplantation has changed transplantation for myelogenous malignancies. Bypassing the oral route to achieve 100% bioavailability translated into improved control over drug administration, with increased safety and reliability of ...
Borje S. Andersson, Stefan O. Ciurea
openaire   +3 more sources

Impact of Early Intrapatient Variability of Tacrolimus Concentrations on the Risk of Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide

Pharmaceuticals, 2022
Tacrolimus (Tac) is a pivotal immunosuppressant agent used to prevent graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (alloHSCT).
Daniel N. Marco, María Queralt Salas, Gonzalo Gutiérrez-García, Inés Monge, Gisela Riu, Esther Carcelero, Joan Ramón Roma, Noemí Llobet, Jordi Arcarons, María Suárez-Lledó, Nuria Martínez, Alexandra Pedraza, Ariadna Domenech, Laura Rosiñol, Francesc Fernández-Avilés, Álvaro Urbano-Ispízua, Montserrat Rovira, Mercè Brunet, Carmen Martínez   +18 more
doaj   +1 more source

Thymopoiesis in Pre- and Post-Hematopoietic Stem Cell Transplantation

Frontiers in Immunology, 2018
Hematopoietic stem cell transplantation (HSCT) is an important therapeutic option for some hematological diseases. However, patients who undergo HSCT acquire a state of immunodeficiency that causes significant mortality. Reconstitution of thymic function
Luis Klaus A. da Rocha, Samar Freschi de Barros, Francine Bandeira, Alexia Bollini, Lucia Helena de A. Testa, Anderson João Simione, Marina de O. e Souza, Lilian P. Zanetti, Leila Cibele S. de Oliveira, Ana Claúdia F. dos Santos, Mair Pedro de Souza, Vergílio Antônio R. Colturado, Jorge Kalil, Clarisse M. Machado, Luiza Guilherme   +14 more
doaj   +1 more source

Comparison between different reduced intensity conditioning regimens in AML/MDS patients in a Latin American center of adult stem cell transplantation

Hematology
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for several hematological diseases. Prospective and retrospective studies have associated myeloablative conditioning regimens with increased non-relapse ...
José Salinas, Yorman Flores, Patricio Rojas, Catherine Gutierrez, Marcela Vidal, Verónica Jara, James Campbell, María José García, Vicente Sandoval, Maximiliano Vergara, Mauricio Ocqueteau, Felipe Palacios, Mauricio Sarmiento   +12 more
doaj   +1 more source

Effect of Inpatient Palliative Care on Quality of Life 2 Weeks After Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2016
Importance During hospitalization for hematopoietic stem cell transplantation (HCT), patients receive high-dose chemotherapy before transplantation and experience significant physical and psychological symptoms and poor quality of life (QOL ...
A. El-Jawahri, T. Leblanc, Harry Vandusen, L. Traeger, J. Greer, W. Pirl, V. Jackson, Jason Telles, Alison M. Rhodes, T. Spitzer, S. Mcafee, Yi-Bin Chen, Stephanie S Lee, J. Temel   +13 more
semanticscholar   +1 more source

Post-stem cell transplant maintenance for pediatric acute leukemias: insights from a Brazilian institution with a Latin American perspective

Frontiers in Oncology
IntroductionIn resource-limited countries, access to advanced therapies like CAR T-cell therapy is often unattainable. Clinical trials face challenges, with pediatric populations frequently excluded or experiencing significant delays. This highlights the
Carla Nolasco Monteiro Breviglieri, Roseane Vasconcelos Gouveia, Roseane Vasconcelos Gouveia, Valéria Cortez Ginani, Valéria Cortez Ginani, Camila Noronha Santos, Milena Reis Santos de Oliveira, Anna Beatriz Willemes Batalha, Gabriella Sayuri de Alencar, Edna Harumi Goto, Juliana Francielle Marques, Marcia Puato Vieira Pupim, Adriana Seber, Adriana Seber   +13 more
doaj   +1 more source

Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF/ATG induced GVHD protective activity and improve haploidentical transplant outcomes

OncoImmunology, 2017
Use of high-dose, post-transplant cyclophosphamide (PTCy) results in low rates of graft-versus-host-disease (GVHD) and favorable immune reconstitution, although with higher rates of relapse and somewhat high rates of graft failure.
Yu Wang, Ying-Jun Chang, Lu Chen, Lan-Ping Xu, Zhi-Lei Bian, Xiao-Hui Zhang, Chen-Hua Yan, Kai-Yan Liu, Xiao-Jun Huang   +8 more
doaj   +1 more source